Neuroscience services and drug development company NeuroDiscovery Ltd has announced that its 100 per cent owned subsidiary, NeuroSolutions Ltd, has struck a $1 million deal with a US pharmaceutical company.
Neuroscience services and drug development company NeuroDiscovery Ltd has announced that its 100 per cent owned subsidiary, NeuroSolutions Ltd, has struck a $1 million deal with a US pharmaceutical company.
Under the terms of the new agreement, NeuroSolutions will provide its specialist electrophysiology services to the as yet un-named company for 12 months.
"In addition to expecting results from our clinical trials, currently underway for NSL-101 and NSL-043, the continuing expansion of our profitable services business in the U.S. market is a key component to our future growth and this agreement marks another milestone for us in this respect," commented Dr Mark Treherne, chairman of NeuroDiscovery.
NeuroDiscovery chief scientific officer, Professor David Spanswick said it looked forward to continuing its successful working relationship with the company.
"Our service business continues to grow and we expect to be able to secure further major contracts in the future."
Subscribe today for award-winning, unbiased and trusted journalism